# FEASIBILITY STUDIES, CLINICAL TRIAL READINESS, GMP/CLINICAL TRIAL MATERIALS

> **NIH NIH N01** · ALBANY MOLECULAR RESEARCH, INC. · 2024 · $89,686

## Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.” 

Drug Manufacturing and Formulation Program; FEASIBILITY STUDIES; CLINICAL TRIAL READINESS; Good Manufacturing Practice; CLINICAL TRIAL MATERIALS

## Key facts

- **NIH application ID:** 11091392
- **Project number:** 271201500005I-P00001-759502200001-1
- **Recipient organization:** ALBANY MOLECULAR RESEARCH, INC.
- **Principal Investigator:** MELISSA ALLARD
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $89,686
- **Award type:** —
- **Project period:** 2022-07-07 → 2027-07-06

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11091392

## Citation

> US National Institutes of Health, RePORTER application 11091392, FEASIBILITY STUDIES, CLINICAL TRIAL READINESS, GMP/CLINICAL TRIAL MATERIALS (271201500005I-P00001-759502200001-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11091392. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*